论文部分内容阅读
单胺氧化酶B(MAO B)的抑制剂丙炔苯丙胺(Deprenyl)为治疗帕金森病的佐药,可抑制MAO B,导致多巴胺(DA)代谢减少。但丙炔苯丙胺最初仅显示在疗效减弱时才有效,不能明显改善用左旋多巴治疗几年的复杂病人经常出现的运动波动、僵直和精神方面的副作用。这说明引起MAOB选择性抑制的丙炔苯丙胺低浓度时可能不足以增强左旋多巴在脑中的作用。为此,作者通过用雄性Wistar鼠制成的体外电生理多巴胺能神经元模型和帕金森病鼠的行为模型,验性评价丙炔苯丙胺是否能真正增强左旋多巴的抗震颤麻痹作用。
Deprenyl, an adjunct to monoamine oxidase B (MAO B), is an adjuvant for the treatment of Parkinson’s disease and inhibits MAO B, leading to a reduction in dopamine (DA) metabolism. However, propranolol initially showed only efficacy at a time when the effect was weakened, and did not significantly improve the frequent motor fluctuations, stiffness and mental side effects in complex patients treated with levodopa for several years. This suggests that low concentrations of propynone, which cause selective inhibition of MAOB, may not be sufficient to enhance the action of levodopa in the brain. To this end, the authors used in-vitro electrophysiological dopaminergic neuronal models made in male Wistar rats and behavioral models of Parkinson’s disease rats to assess whether propargyl can actually enhance anti-paralytic paralysis of levodopa.